XBiotech Inc
XBITXBiotech Inc (XBIT) is a biotechnology company focused on developing and commercializing investigational human therapeutic antibodies for the treatment of various diseases. It is known for its research on immune-based therapies, particularly its proprietary True Human™ monoclonal antibodies. The company's approach emphasizes safety and efficacy through the use of genetically engineered antibodies derived from human sources.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| July 23, 2021 | $2.10 | 2021-07-15 | 2021-07-16 |
Dividends Summary
- Consistent Payer: XBiotech Inc has rewarded shareholders with 1 dividend payments over the past 0 years.
- Total Returned Value: Investors who held XBIT shares during this period received a total of $2.10 per share in dividend income.
- Latest Payout: The most recent dividend of $2.10/share was paid 1821 days ago, on July 23, 2021.
Company News
XBiotech announced that its IND application for the V-SPINE Phase II clinical trial evaluating vilamakitug (an IL-1α antibody) for treating active axial spondyloarthritis has completed FDA review without a clinical hold. The double-blind, placebo-controlled study will enroll 150 participants and evaluate the drug's efficacy and safety, with the ...
Wolf Haldenstein Adler Freeman & Herz LLP is investigating XBiotech for potential securities law violations after the company announced issues with its Phase II rheumatoid arthritis drug study, leading to a 29% stock price drop.
XBiotech has suspended its clinical program on rheumatological conditions pending a review of the results from its recent Phase II study on rheumatoid arthritis. The study did not meet its primary endpoint due to substantial irregularities, and the company is now evaluating the implications of the results before deciding on the next steps for its...
XBiotech has announced that it is halting its clinical program for rheumatological diseases after its recent Phase II trial for rheumatoid arthritis failed to meet its primary endpoint due to significant irregularities that made the results difficult to interpret. The company is now evaluating the data to understand the implications and determine...
The global cancer cachexia market is expected to grow from $2.47 billion in 2024 to $3.14 billion by 2028, driven by increased cancer prevalence, enhanced treatment options, and greater awareness among healthcare professionals.
